The total consideration paid and the allocation to assets acquired and liabilities assumed was (in thousands): | | | | | | | Consideration | | | Cash consideration to acquire Chimerix’s outstanding common stock | $ | 802,023 | | | Cash consideration for Chimerix’s outstanding equity awards | 142,131 | | | Total cash consideration paid to Chimerix | 944,154 | | | Transaction costs | 13,237 | | | Total consideration | $ | 957,391 | | | | | Assets Acquired and Liabilities Assumed | | | Cash | $ | 99,338 | | | In-process research and development | 905,362 | | | Accrued liabilities | (53,066) | | | Other assets and liabilities | 5,757 | | | Total net assets acquired | $ | 957,391 | |
|